However, blockade of PD-1 signaling with anti-PD-1/PD-L1 antibodies not only reinvigorates preexisting tumor-specific T cells but also augments PD-1 + Tregs; therefore, the balance of PD-1 expression between CD8 + T cells and Treg cells in the TME needs more attention [19]. The gene discussed is CD8A; the disease is neoplasm.